Perioperative medicine & outcomes
Dexamethasone and persistent wound pain: a prespecified analysis of the randomised Perioperative Administration of Dexamethasone and Infection (PADDI) trial
Primary resultResult — go to the resultRelative risk 1.2 95% CI 1.06–1.41Authors' conclusion
Administration of dexamethasone 8 mg i.v. was associated with an increase in the risk of pain in the surgical wound 6 months after surgery.
Study context
- Population
- Patients undergoing non-urgent noncardiac surgerymodified ITT population
- Participants
- 8,478 patients
- Comparison
- Dexamethasone 8 mg IV vs placebo after induction of anaesthesia
- Dexamethasonen = 4,258
- Placebon = 4,220reference
- Primary endpoint
- Incidence of pain in the surgical wound
- Follow-up
- 6 months
Methodological detailsprespecified, embedded superiority substudy, placebo-controlled
- Prespecified
- Embedded superiority substudy
- Placebo-controlled
Primary result
As reported in the abstract
Relative risk
1.2
95% CI 1.06–1.41
P = 0.003
Events by treatment group
Dexamethasone vs Placebo
RR 1.2 (95% CI 1.06–1.41); P = 0.003
Secondary outcomes
Median
| Outcome | Dexamethasone | Placebo | P value |
|---|---|---|---|
| Maximum pain score at rest, first 3 POD · first 3 postoperative days | 5 (IQR 3.0–8.0) | 6 (IQR 3.0–8.0) | P < 0.001 |
| Maximum pain score on movement, first 3 POD · first 3 postoperative days | 7 (IQR 5.0–9.0) | 8 (IQR 6.0–9.0) | P < 0.001 |
Postoperative pain severity as predictor of chronic postsurgical pain
- Severity of postoperative pain not predictive of chronic postsurgical pain
Chronic postsurgical pain severity and neuropathic features
- Did not differ between treatment groups
Original publication
Dexamethasone and persistent wound pain: a prespecified analysis of the randomised Perioperative Administration of Dexamethasone and Infection (PADDI) trial. Br J Anaesth. Published 23 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →